The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

The number of people making five or more emergency visits to hospital a year with lung difficulties has almost tripled in some parts of England, an analysis has found. The charity Asthma + Lung UK ...

China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...

If the symptoms resolve on this trial of treatment, then try stopping the inhaler and see if the symptoms recur. If they do recur, or an acute episode of wheeze occurs, then low-dose ICS should be ...

Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated. Several ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an agreement to acquire Chimerix CMRX. Meanwhile, other pi ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

StockNews.com downgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning. Separately, Scotiabank assumed ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Join Nic Chahine ...